| Document |
Document Title |
|
WO/2024/051762A1 |
The anti-TROP2/EGFR antibodies, and antibody drug conjugates derived therefrom, specifically bind to at least two different antigens EGFR and TROP2.
|
|
WO/2024/055039A1 |
Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the sub...
|
|
WO/2024/054040A1 |
The present invention relates to novel use of an oncolytic virus, and relates to an intravenously injectable composition for repeated administration, comprising, as an active ingredient, an oncolytic virus in which expression of a thymid...
|
|
WO/2024/051383A1 |
Provided are an anti-Trop2 antibody, a conjugate comprising said antibody, and a use thereof. Specifically, provided are an anti-Trop2 single-domain antibody, a long-acting anti-Trop2 antibody formed from connecting, in tandem, an anti-T...
|
|
WO/2024/051804A1 |
The present invention provides an anti-ILT4 antibody and pharmaceutical use thereof.
|
|
WO/2024/051106A1 |
A preparation and use of an anti-IL4i1 nano antibody. The anti-IL4i1 nano antibody has three unique complementarity-determining regions CDR1, CDR2, and CDR3, and nine sequences of the anti-IL4i1 nano antibody are selected in total. Furth...
|
|
WO/2024/052906A1 |
Disclosed herein are micropatterned surfaces, particularly in the shape of micro-brushes having a base and a plurality of elongated elements. The micropatterned surfaces suitably biofunctionalized are particularly useful for activation a...
|
|
WO/2024/050648A1 |
Methods of treating a subject who has or is at risk of having a chemo-resistant tumor comprising a step of administering a pharmaceutical composition comprising a self-assembled polypeptide complex, which methods result in slowing, inhib...
|
|
WO/2024/051763A1 |
The present invention relates to an inhibitor having a quinazoline heterocyclic structure for treating cancer. Specifically, the present invention relates to a derivative having a quinazoline heterocyclic structure as shown in formula (I...
|
|
WO/2024/054518A1 |
Provided are systems and methods of enhancing tumor-reactive immune populations such as tumor infiltrating lymphocytes from patient-derived organoids. Also, provided herein are systems and methods of expanding and reprogramming tumor-rea...
|
|
WO/2024/051667A1 |
Disclosed is a substituted triazole compound having AXL inhibitory activity represented by formula (I), which is used for treating and/or preventing AXL receptor tyrosine kinase-induced disorders.
|
|
WO/2024/052663A1 |
A pharmaceutical composition comprising an NEK1 inhibitor and uses thereof in the treatment of cancer.
|
|
WO/2024/054993A1 |
The present disclosure provides a composition comprising a recombinant adenoassociated virus (rAAV) vector comprising an AAV capsid, wherein the rAAV comprises a vector genome packaged within the capsid, wherein the vector genome compris...
|
|
WO/2024/053887A1 |
This invention relates to a Copine1 gene marker for prognosing the metastasis of HER2-positive breast cancer and a use thereof. Specifically, the present invention relates to a biomarker composition for prognosing the metastasis of HER2-...
|
|
WO/2024/052675A1 |
The disclosure relates to a method of treating head and neck cancer, and to a population of modified immunoresponsive cells expressing a heterologous TCR for use in such method.
|
|
WO/2024/051223A1 |
Disclosed herein are a pharmaceutical composition and use thereof. The pharmaceutical composition comprises an anti-CTLA4 and anti-PD-1 bispecific antibody and an anti-PD-1 and anti-VEGFA bispecific antibody. The pharmaceutical compositi...
|
|
WO/2024/051765A1 |
Provided is a method for promoting T cell proliferation and function by means of intracellular CD59, comprising silencing a CD59 gene in a T cell. Further provided is a nucleic acid molecule for CD59 gene interference. The target sequenc...
|
|
WO/2024/051831A1 |
The present invention relates to a constitutive chimeric cytokine receptor, comprising an extracellular domain and a constitutively activated IL-7R mutant. The extracellular domain consists of an effector molecule capable of remodeling t...
|
|
WO/2024/051752A1 |
Provided are bispecific and multi-specific antibodies that include an agonist anti-4-1BB single-domain antibody capable of effector function-mediated tumor inhibition. In addition, these agonist antibodies, in the absence of tumor antige...
|
|
WO/2024/052692A1 |
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein RL, L and RR are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatm...
|
|
WO/2024/054953A1 |
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.
|
|
WO/2024/054591A1 |
Provided herein are bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (Raf, such as c-Raf, A-Raf, and/or B-RAF).
|
|
WO/2024/051766A1 |
The present disclosure relates to a compound of formula (I) or a salt, an enantiomer, a diastereomer, an isotope-enriched analogue, a solvate, a prodrug or a polymorph thereof, and the use thereof. Further provided in the present disclos...
|
|
WO/2024/053929A1 |
The present invention relates to an anti-VISTA monoclonal antibody and a use thereof, and more specifically, to an anti-VISTA monoclonal antibody, a functional fragment thereof, and a use thereof for preventing or treating cancer.
|
|
WO/2024/046454A1 |
The present application relates to a heteroaryl-substituted pyridopyrrolidone derivative, and a pharmaceutical composition and the use thereof. The heteroaryl-substituted pyridopyrrolidone derivative has a structure as shown in formula (...
|
|
WO/2024/049046A1 |
The present disclosure relates to a peptide binding to Trop 2 and a use thereof, wherein, in an attempt to find a peptide having an ability of specifically binding to Trop 2, a peptide (amino acid sequence: CSTLNVESC) that selectively bi...
|
|
WO/2024/050023A1 |
The present disclosure relates to the treatment of a cancer in a human subject where the treatment includes continuing administration of a T cell receptor (TCR) therapy in subjects whose ctDNA levels do not exceed baseline following admi...
|
|
WO/2024/046221A1 |
Disclosed herein are compounds or pharmaceutically acceptable salts thereof that are useful as EGFR inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions...
|
|
WO/2024/046239A1 |
The present invention relates to a specific recombinant humanized monoclonal antibody targeting human GPRC5D and an application thereof, can be used in ELISA and flow detection methods, and can be used for diagnosis and treatment targeti...
|
|
WO/2024/050500A1 |
Combined administration of a selective glucocorticoid receptor modulator (SGRM; e.g., relacorilant or exicorilant) and a cancer therapeutic (e.g., a taxane or antiandrogen) is useful for identifying elevated cortisol activity in patients...
|
|
WO/2024/046471A1 |
The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
|
|
WO/2024/046420A1 |
The present disclosure relates to a fused bicyclic compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a fused bicyclic compound as shown in general formula (I), a ...
|
|
WO/2024/046929A1 |
This invention provides a method of modifying a cyanobacterial or fungal toxin for use as a payload in an antibody-drug conjugate, comprising the following steps: selecting a cyanobacterial or fungal toxin having a base structure known t...
|
|
WO/2024/049348A1 |
The present invention provides a modified immune cell, which comprises a T cell receptor (TCR) capable of specifically targeting hepatitis B surface antigen (HBsAg) and a chimeric conversion receptor. The chimeric conversion receptor use...
|
|
WO/2024/050318A1 |
In one aspect, disclosed herein are novel multimeric costimulatory agonistic constructs comprising said monomers for expanding tumor infiltrating lymphocytes (TILs) in vitro or ex vivo said methods comprising obtaining TILs and culturing...
|
|
WO/2024/050524A1 |
Provided herein are compositions for increasing Apolipoprotein L1 (ApoL1) in target cells. The ApoL1 can be a recombinant protein or an endogenous protein optionally in a ApoL1-containing complex. Antibodies and other binding molecules t...
|
|
WO/2023/160569A9 |
This disclosure relates to compounds of Formula (I) as PGE2 receptor antagonists or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/049926A1 |
Disclosed herein are methods for treating cancer comprising administering to a subject a daily dose of Compound A, or a pharmaceutically acceptable salt thereof, in combination with a CDK4/6 inhibitor.
|
|
WO/2024/047172A1 |
The present invention relates to an integrin alpha10 antibody drug conjugate and medical uses thereof.
|
|
WO/2024/048478A1 |
Disclosed is a novel treatment method in which the effectiveness of cancer treatment is improved by using an immune checkpoint regulator in combination. An anticancer drug according to the present invention has, as an active ingredient, ...
|
|
WO/2024/048615A1 |
The present invention provides a method for producing a compound represented by formula (I), the method including a step that reacts a compound represented by formula (II) with a compound represented by formula (III).
|
|
WO/2024/048644A1 |
This carrier for delivering a target substance to MUC6 expression-negative cancer tissues contains a molecule having the activity of binding to mannose. The cancer tissues may be MUC6 expression-negative gastric cancer tissues arising fr...
|
|
WO/2024/050370A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2024/045414A1 |
The present invention provides a heptamethine cyanine dye-artemisinin conjugate and use thereof, and belongs to the technical field of cancer therapy. The heptamethine cyanine dye-artemisinin conjugate provided by the present invention c...
|
|
WO/2024/046389A1 |
The present invention relates to a combination therapy, comprising an anti-TIGIT antibody or an antigen-binding fragment thereof and an anti-CTLA-4 antibody or an antigen-binding fragment thereof. The present invention also relates to co...
|
|
WO/2024/046246A1 |
Use of a mitoxantrone liposome and capecitabine in treating nasopharyngeal carcinoma, in particular recurrent and/or metastatic nasopharyngeal carcinoma. The present invention further provides a method for treating nasopharyngeal carcino...
|
|
WO/2024/048541A1 |
This medicament, which contains, together or separately in combination with a CDK inhibitor, an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, is useful for treating and/or preventing cancer.
|
|
WO/2024/050366A1 |
Described herein are methods, devices, and systems for identifying a subset of a plurality of features, using one or more feature importance metrics, for training and using a homologous repair deficiency (HRD) classification model. Furth...
|
|
WO/2024/048555A1 |
The present invention relates to a therapeutic or prophylactic drug, a combination, a pharmaceutical composition, a preparation, a therapeutic or prophylactic method, and a growth suppressor for ALK fusion gene-positive cancer having tem...
|
|
WO/2024/049161A1 |
The present invention relates to a novel antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1, a chimeric antigen receptor comprising an antigen-binding variable fragment of the antibody, immune cells expres...
|
